To examine the association between trial sponsorship and conflicts of interest (COI) with clinical trial conclusions for prostate cancer trials related to radiotherapy.
The MEDLINE database was searched for all prostate cancer clinical trials published between 2004 and 2013 and identified 1396 studies. Two investigators independently identified trials published in the English language of ≥30 patients, and extracted relevant data. Clinical trials were classified according to trial characteristics, sponsorship source and type, COI, and study conclusion, and analyzed by univariable and multivariable logistic regression.
Of 240 eligible trials, 160 (67.5%) evaluated drugs without radiotherapy, 60 (25%) involved radiotherapy, and 18 (7.5%) involved procedures without radiotherapy. Of the 60 radiotherapy trials eligible for analysis, positive sponsorship and potential COI were present in 58.3% and 20% of trials, respectively. Study conclusions were positive, negative, or neutral in 78.3%, 5%, and 16.7% of trials, respectively. No association was found between positive conclusions and either industry support of potential COI. Positive conclusions were reported in 86.7% and 83.3% of trials with sponsorship and COI, respectively, as compared with 75.6% and 77.1% of those without sponsorship (P=0.37) and COI (P=0.64). Sponsorship was significantly associated with radiotherapy trials combined with drugs (odds ratio 5.5, P=0.01) and higher-risk disease (odds ratio 4.71, P=0.01).
The presence of sponsorship was associated with radiotherapy trials involving drugs or studying higher-risk prostate cancer. However, there were no identified associations between study conclusion and sponsorship type or COI.
Supplemental Digital Content is available in the text.
*Department of Radiation Oncology, Sírio-Libanês, São Paulo, Brazil
∥Department of Radiation Oncology, Sirio-Libanês, Hospital, Brasília, DF
‡Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo
†Department of Radiology and Oncology, Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
§Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
¶Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
D.A.H.: Grant: Novartis, Consultant: Augmenix, Advisory Board: Myriad and Medivation, Speaker: Varian. F.Y.F.: Advisory Boards: Medivation/Astellas, GenomeDx, Nanostring, Celgene. Grant Funding: Varian, Medivation/Astellas, Celgene. D.E.S.: Supported by the Prostate Cancer Foundation 2014 Young Investigator Award. The other authors declare no conflicts of interest.
Reprints: Daniel E. Spratt, MD, Department of Radiation Oncology, University of Michigan Medical Center, 1500 East Medical Center Dr, Ann Arbor, MI 48109-0010. E-mail: email@example.com.